NEUROBEHAVIORAL HEALTH COMPANY BLACKTHORN HAULS IN $76 MILLION FROM GV TO TREAT MENTAL DISORDERS

BlackThorn Therapeutics, a neurobehavioral health company using machine learning to create personalized medicine for mental health, is placing big bets on its technological approach to finding drugs that work will put it ahead of the competition. That has caught the eye of GV and other biotech investors who have poured in another $76 million USD in Series B funding to the start up.

Other notable names taking part in the latest financing round include Scripps Research, Johnson & Johnson Innovation and a bevy of other biotech investment firms, including Polaris Partners, Premier Partners, Vertex Ventures HC, Alexandria Venture Investments, Altitude Life Science Ventures, ARCH Venture Partners and Biomatics Capital.

Notable Quotes: “BlackThorn was founded to bring new therapies to patients by applying advances in computational sciences to address patient heterogeneity, one of the biggest historical challenges in the field of neuropsychiatric drug development.” -BlackThorn’s president and COO Bill Martin, PhD.